sever
human
monoclon
antibodi
hmab
antibodi
fragment
includ
best
character
term
structurefunct
fab
exhibit
rel
potent
broad
neutral
activ
howev
elicit
antibodi
vivo
vaccin
immunogen
base
envelop
glycoprotein
env
success
highli
diverg
closest
correspond
germlin
antibodi
less
diverg
hypothes
rel
high
degre
specif
somat
hypermut
may
preclud
bind
envelop
glycoprotein
env
closest
germlin
antibodi
identifi
antibodi
intermedi
pathway
matur
could
help
design
novel
vaccin
immunogen
guid
immun
system
enhanc
elicit
support
hypothesi
previous
found
germlinelik
monoval
bival
scfv
fc
fusion
protein
igg
lack
measur
bind
env
measur
elisa
sensit
rang
present
evid
confirm
expand
find
panel
env
contrast
germlinelik
scfv
bound
env
high
nm
affin
begin
explor
matur
pathway
antibodi
identifi
sever
possibl
intermedi
antibodi
test
neutral
activ
intermedi
antibodi
neutral
isol
rel
weak
potenc
contrast
germlinelik
scfv
neutral
subset
test
isol
compar
effici
matur
result
could
help
explain
rel
high
immunogen
coreceptor
virus
bind
site
abund
antibodi
patient
antibodi
well
matur
pathway
also
help
identifi
antigen
bind
specif
germlin
intermedi
antibodi
togeth
env
could
use
conceptu
novel
type
candid
vaccin
candid
vaccin
base
two
immunogen
could
help
guid
immun
system
complex
matur
pathway
elicit
antibodi
similar
ident
antibodi
known
properti
elicit
broadli
crossreact
neutral
antibodi
bnab
vivo
rare
thought
like
due
protect
conserv
structur
viru
envelop
glycoprotein
env
variabl
loop
extens
glycosyl
occlus
within
oligom
conform
mask
rapid
gener
mutant
outpac
develop
antibodi
number
envspecif
hmab
identifi
sever
exhibit
neutral
activ
primari
isol
differ
clade
includ
igg
igg
igg
igg
igg
igg
fab
fab
best
character
consid
exhibit
averag
broadest
potent
neutral
activ
exhibit
compar
even
potent
broad
neutral
activ
howev
depend
size
smallest
fragment
scfv
potent
follow
fab
igg
fullsiz
antibodi
format
significantli
less
potent
although
still
neutral
isol
exist
bnab
fuel
hope
develop
efficaci
hiv
vaccin
achiev
provid
immunogen
contain
epitop
antibodi
appropri
design
howev
spite
tremend
amount
research
goal
antibodybas
effect
vaccin
base
appropri
design
expos
empir
found
vaccin
immunogen
achiev
inabl
achiev
elicit
bnab
human
low
frequenc
hivinfect
human
potent
bnab
strongli
suggest
still
unknown
fundament
immunolog
mechan
allow
hiv
evad
elicit
bnab
understand
mechan
could
provid
novel
tool
develop
efficaci
vaccin
previous
analyz
sequenc
known
bnab
found
highli
diverg
germlin
antibodi
especi
highli
somat
hypermut
rel
less
diverg
germlin
antibodi
hypothes
rel
high
degre
specif
somat
hypermut
may
preclud
bind
envelop
glycoprotein
env
closest
germlin
antibodi
identifi
antibodi
intermedi
pathway
matur
could
help
design
novel
vaccin
immunogen
guid
immun
system
enhanc
elicit
support
hypothesi
previous
found
germlinelik
monoval
bival
scfv
fc
fusion
protein
igg
lack
measur
bind
env
measur
elisa
sensit
rang
contrast
germlinelik
scfv
bound
env
high
nm
affin
present
evid
confirm
expand
find
panel
env
describ
identif
possibl
intermedi
antibodi
could
serv
reagent
identif
new
vaccin
immunogen
help
guid
immun
system
matur
pathway
previous
found
germlinelik
bind
env
rel
high
strength
low
slightli
lower
matur
antibodi
figur
character
interact
explor
rel
contribut
heavi
light
chain
interact
gener
express
purifi
hybrid
molecul
contain
heavi
chain
combin
light
chain
germlinelik
figur
hybrid
matur
heavi
chain
germlinelik
light
chain
bound
better
germlinelik
similarli
matur
underli
domin
role
heavi
chain
determin
bind
specif
affin
figur
sinc
share
germlin
light
chain
v
j
gene
anoth
hybrid
matur
heavi
chain
matur
light
chain
gener
hybrid
bound
weaker
germlin
figur
unlik
due
improp
protein
fold
sinc
solubl
express
particular
hybrid
compar
matur
germlinelik
hybrid
case
hybrid
molecul
bound
env
suggest
heavi
chain
matur
like
germlinelik
domin
interact
figur
test
neutral
activ
germlinelik
scfv
rel
matur
antibodi
use
panel
pseudovirus
env
isol
clade
b
c
matur
neutral
effici
concentr
use
germlinelik
neutral
b
clade
dual
tropic
isol
almost
effici
matur
one
lost
complet
neutral
abil
b
clade
tropic
isol
well
isol
clade
figur
confirm
observ
dose
respons
curv
construct
matur
germlinelik
three
repres
isol
figur
matur
germlinelik
exhibit
similar
bal
pseudoviru
complet
lack
neutral
germlinelik
iiib
data
although
base
limit
number
isol
test
indic
possibl
mechan
could
evolv
clade
tropism
specif
neutral
antibodi
rel
broadli
neutral
antibodi
acquir
somat
mutat
howev
note
activ
measur
scfv
format
discuss
fullsiz
less
potent
scfv
matur
pathway
vivo
like
complex
bind
characterist
scfv
variou
form
includ
matur
germlin
subsequ
figur
term
germlin
conveni
represent
germlinelik
antibodi
studi
hybrid
variou
heavi
light
chain
c
gel
analysi
purifi
matur
germlin
hybrid
scfv
molecular
weight
marker
matur
germlin
scfv
respect
c
molecular
weight
marker
hybrid
scfv
matur
heavi
chain
germlin
light
chain
hybrid
matur
heavi
chain
matur
heavi
chain
b
bind
purifi
protein
shown
c
respect
bal
abbrevi
subsequenct
figur
follow
math
matur
heavi
chain
germl
germlin
light
chain
matl
matur
light
chain
germh
germlin
heavi
chain
previous
found
germlinelik
lack
measur
bind
env
elisa
assay
confirm
extend
observ
panel
env
case
found
germlinelik
format
scfv
igg
lack
measur
bind
panel
env
figur
contrast
expect
matur
bound
strongli
test
env
figur
began
identifi
possibl
intermedi
matur
pathway
introduc
critic
residu
found
matur
back
germlin
framework
start
sever
reason
first
heavi
chain
like
major
determin
bind
indic
crystal
structur
complex
secondli
amino
acid
substitut
germlin
matur
form
similar
natur
contrast
three
mutat
matur
result
amino
acid
differ
germlin
counterpart
seri
mutant
gener
surround
germlin
region
describ
method
order
prevent
potenti
poor
express
fold
certain
mutant
distort
data
interpret
mutant
investig
express
purifi
homogen
scfv
scfvfc
solubl
fusion
protein
figur
germlinelik
antibdi
also
express
igg
format
fig
initi
screen
one
singl
high
antibodi
concentr
found
singl
mutat
suffici
confer
detect
bind
abil
germlin
addit
mutat
increas
bind
abil
significantli
figur
bind
select
scfv
analyz
bal
elisa
left
panel
two
concentr
includ
bar
closer
yaxi
scfv
use
bsa
antigen
includ
specif
control
right
panel
maximum
valu
yaxi
show
od
elisa
assay
set
reflect
weak
bind
bind
matur
reach
satur
concentr
indic
figur
determin
strength
bind
variou
format
elisa
perform
use
bal
antigen
variou
scfv
scfvfc
b
indic
analyz
bind
c
competit
elisa
variou
scfv
origin
scfvfc
fix
amount
variou
scfv
premix
increas
amount
origin
scfvfc
block
buffer
appli
elisa
plate
coat
bal
amount
bound
scfv
measur
use
antihishrp
specif
competit
variou
form
bind
bal
fix
amount
ug
mix
increas
amount
variou
fusion
protein
block
buffer
ad
elisa
plate
coat
bal
bound
detect
antihishrp
confirm
data
obtain
initi
screen
singl
high
concentr
perform
elisa
use
rang
concentr
variou
scfv
scfvfc
bind
germlin
mutant
consist
detect
figur
b
interestingli
hybrid
matur
light
chain
germlin
heavi
chain
also
display
bind
abil
albeit
weak
figur
b
avid
effect
evid
bind
scfv
correspond
scfvfc
compar
figur
b
noteworthi
germlinelik
consist
show
bind
even
highest
concentr
bind
characterist
intermedi
summar
tabl
ad
two
layer
specif
control
addit
bsa
use
control
antigen
experi
first
found
weak
bind
detect
intermedi
complet
compet
matur
figur
intermedi
compet
bind
competit
proport
bind
abil
germlinelik
hand
show
competit
figur
result
indic
two
mutat
could
play
role
pathway
germlin
matur
tabl
summari
bind
characterist
matur
germlinelik
intermedi
scfv
scfvfc
determin
elisa
antigen
bal
db
bind
na
test
bind
affin
rang
germhmatl
germlin
heavi
chain
fuse
matur
light
chain
mathgerml
matur
heavi
chain
fuse
germlin
light
chain
neutral
abil
matur
germlinelik
variou
intermedi
scfvfc
format
test
panel
hiv
env
pseudotyp
virus
matur
neutral
effici
isol
clade
b
except
independ
isol
matur
also
fail
inhibit
two
isol
clade
c
includ
isol
agreement
previou
find
effici
b
clade
isol
none
intermedi
display
signific
neutral
abil
except
hybrid
matur
heavi
chaingermlin
light
chain
mathgerml
rel
high
bind
affin
nm
neutral
iiib
modest
activ
concentr
significantli
higher
concentr
need
bind
figur
result
indic
potenti
intermedi
antibodi
may
exert
select
pressur
gener
mutant
accumul
number
somat
mutat
matur
contribut
increment
increas
bind
env
test
variou
somat
mutat
contribut
self
antigen
bind
use
three
human
cell
line
flow
cytometri
analysi
found
matur
bind
strongli
cell
figur
agreement
previou
data
hayn
group
germlinelik
intermedi
small
number
mutat
display
much
lower
although
measur
activ
cell
line
figur
interestingli
intermedi
larg
number
mutat
hybrid
mathgerml
germhmatl
antibodi
test
show
significantli
higher
human
cell
bind
approach
level
display
matur
find
indic
specif
bind
env
self
antigen
probabl
acquir
concomitantli
matur
process
progress
experi
determin
natur
human
molecul
recogn
extens
somat
mutat
found
identifi
broadli
neutral
hiv
antibodi
hiv
specif
antibodi
contrast
potent
neutral
antibodi
acut
infect
antibodi
possess
mutat
compar
germlin
sequenc
knowledg
whether
germlinelik
antibodi
correspond
antibodi
possess
neutral
activ
somat
mutat
contribut
bind
neutral
function
limit
begin
increas
understand
properti
antibodi
matur
pathway
analyz
bind
neutral
abil
matur
germlin
form
two
neutral
antibodi
modestli
neutralz
antibodi
target
highli
conserv
epitop
correspond
germlin
antibodi
scfv
format
display
high
affin
env
test
studi
neutral
effici
sever
isol
intriguingli
neutral
isol
belong
b
clade
either
tropic
dual
tropic
hand
matur
scfv
neutral
isol
test
isol
b
c
clade
data
suggest
first
germlin
antibodi
certain
epitop
env
similarli
antibodi
acut
infect
possess
neutral
abil
secondli
mutat
process
shift
expand
antibodi
bind
epitop
becam
inclus
lead
broadli
neutral
antibodi
notion
support
previou
observ
synthet
inhibitor
base
epitop
partial
overlap
germlin
reveal
competit
elisa
tendenc
neutral
b
clade
tropic
virus
contrast
germlinelik
epitop
overlap
significantli
matur
germlin
also
reveal
competit
elisa
base
data
one
specul
origin
germlin
antibodi
recogn
b
clade
tropic
isol
subsequ
mutat
expand
target
includ
b
clade
tropic
isol
clade
seem
follow
typic
antibodi
matur
pathway
might
explain
partial
predomin
presenc
antibodi
hiv
patient
due
fact
epitop
appear
readili
avail
germlin
antibodi
recognit
remain
seen
germlin
counterpart
antibodi
possess
antigen
bind
neutral
abil
observ
contrast
appear
follow
differ
pathway
germlin
lack
observ
bind
panel
env
confirm
expand
origin
observ
lack
measur
bind
germlinelik
one
env
systemat
mutat
amino
acid
residu
matur
correspond
locat
germlin
identifi
sever
possibl
intermedi
differ
stage
along
matur
pathway
importantli
increas
bind
env
associ
increas
number
somat
mutat
intermedi
seem
close
relat
increas
bind
human
antigen
reveal
potenti
interest
interplay
env
human
self
antigen
origin
matur
propos
previou
studi
base
lack
bind
germlin
hiv
env
one
altern
antigen
selfantigen
includ
like
respons
initi
activ
b
cell
express
germlinelik
antibodi
somat
mutat
ensu
activ
may
enabl
intermedi
bind
antigen
includ
env
fact
singl
mutat
confer
detect
germlinelik
bind
env
found
studi
indic
scenario
possibl
note
howev
similar
select
phage
display
procedur
therefor
relev
well
intermedi
binder
identifi
studi
vivo
situat
remain
hypothet
intermedi
antibodi
current
use
reagent
identifi
molecul
could
serv
primari
immunogen
initi
matur
antibodi
primari
immunogen
found
could
use
combin
appropri
design
env
expos
epitop
lack
immunodomin
epitop
conceptu
new
two
immunogen
approach
guid
immun
system
complex
matur
pathway
known
antibodi
high
activ
gener
could
use
help
design
vaccin
immunogen
also
diseas
includ
cancer
primer
use
studi
purchas
invitrogen
carlsbad
ca
bal
provid
tim
fout
univers
maryland
baltimor
md
recombin
protein
provid
christoph
broder
usuh
bethesda
md
codonoptim
clone
express
vector
invitrogen
attach
tag
c
terminu
transfect
freestyl
cell
express
accord
manufactur
suggest
protocol
secret
purifi
use
nickl
column
cultur
medium
qiagen
hilden
germani
scfv
dna
correspond
matur
germlinelik
synthes
genescript
genescript
piscatawi
nj
vh
antibodi
link
vl
via
gggg
linker
scfv
fragment
clone
plasmid
provid
denni
burton
scripp
institut
la
jolla
cal
express
bacteria
dna
fragment
encod
variou
scfv
antibodi
fuse
fc
human
clone
mammalian
cell
express
vector
invitrogen
express
scfvfc
fusion
protein
vh
vl
germlin
graft
vector
provid
denni
burton
convers
format
degener
primer
primer
atg
gga
tgg
atc
aac
sct
krc
aat
ggt
aac
ama
aaa
tat
tca
cag
use
overlap
pcr
replac
residu
posit
germlin
correspond
residu
matur
form
collect
germlin
variant
contain
one
two
three
residu
matur
form
gener
process
scfv
express
e
coli
strain
transform
scfv
construct
describ
singl
clone
inocul
supplement
unit
ampicillin
glucos
incub
shake
reach
iptg
ad
achiev
final
concentr
mm
cultur
continu
shake
overnight
cell
collect
lyse
polymyxin
b
sigma
st
loui
pb
supernat
subject
ninta
agaros
bead
qiagen
purif
solubl
scfv
variou
scfvfc
construct
well
germlin
igg
construct
transfect
freestyl
cell
polyfectin
transfect
agent
invitrogen
four
day
transfect
cultur
medium
collect
secret
scfvfc
igg
protein
purifi
use
proteina
sepharos
column
ge
healthcar
piscataway
nj
differ
protein
antigen
dilut
pb
buffer
concentr
rang
coat
well
plate
overnight
plate
block
pb
dri
milk
buffer
antibodi
variou
format
dilut
block
buffer
appli
elisa
plate
mouseantihishrp
use
detect
tag
c
terminu
end
scfv
elisa
mouseantihuman
fchrp
use
detect
scfvfc
igg
bind
abt
ad
well
od
taken
minut
afterward
estim
binder
data
gener
dose
respons
bind
analyz
use
weight
leastsquar
fit
data
function
hill
equat
hiv
env
pseudotyp
viru
prepar
neutral
perform
previous
describ
activ
pseudoviru
isol
without
antibodi
treatment
express
percentag
correspond
control
viru
without
antibodi
treatment
averag
percentag
standard
deviat
calcul
